Aptose Biosciences (APS) Price & Analysis

Compare

147 Followers

APS Stock Chart & Stats

C$2.31

-C$0.01(-3.08%)

At close: Jan 08 4:00 PM EST

C$2.31

-C$0.01(-3.08%)

Day’s Range― - ―

52-Week RangeC$1.02 - C$16.50

Previous CloseN/A

Volume48.76K

Average Volume (3M)3.35K

Market Cap

$5.10M

Enterprise ValueC$16.69M

Total Cash (Recent Filing)$553.00K

Total Debt (Recent Filing)$11.38M

Price to Earnings (P/E)―

Beta-1.08

Next Earnings

Mar 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.82

Shares Outstanding2,552,429

10 Day Avg. Volume4,664

30 Day Avg. Volume3,346

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)-34.40

Price to Sales (P/S)0.00

P/FCF Ratio-4.34

Enterprise Value/Market Cap3.27

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.83

Forecast

1Y Price Target

$2.42

Price Target Upside4.87% Upside

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentTuspetinib is a highly differentiated kinase inhibitor with favorable safety and broad activity across difficult-to-treat AML subpopulations, including those with TP53, RAS, and FLT3 mutations.

Financial CollaborationAptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement to provide necessary additional funding and accelerate clinical development of tuspetinib.

Bears Say

Cash ReservesThe company ended the year with $6.7 million in cash, which management believes should provide runway for ongoing operations through April 2025.

Aptose Biosciences News

Aptose Biosciences downgraded to Neutral from Buy at Alliance Global

Alliance Global downgraded Aptose Biosciences (APTOF) to Neutral from Buy with a C$2.41 price target The firm does...

7d ago

Aptose Biosciences to be Acquired by Hanmi Pharmaceuticals

Aptose Biosciences ( ($TSE:APS) ) has provided an update. On November 18, 2025, Aptose Biosciences Inc. entered into...

6d ago

Aptose Biosciences to be Acquired by Hanmi Pharmaceutical

An update from Aptose Biosciences ( ($TSE:APS) ) is now available. Aptose Biosciences has entered into an agreement...

12d ago

Aptose Biosciences Reports Financial Challenges in Q3 2025

Aptose Biosciences ( ($APTOF) ) has released its Q3 earnings. Here is a breakdown of the information Aptose...

17d ago

Aptose Biosciences Reports Promising Results in AML Therapy Trials

Aptose Biosciences ( ($TSE:APS) ) just unveiled an announcement. Aptose Biosciences announced promising results from its TUSCANY clinical...

18d ago

Aptose Biosciences’ TUSCANY Study Highlighted at ASH 2025

Aptose Biosciences ( ($TSE:APS) ) just unveiled an update. On November 3, 2025, Aptose Biosciences announced that an...

28d ago

Aptose Biosciences’ Tuspetinib Study: A Potential Game-Changer in Leukemia Treatment

Aptose Biosciences Inc. (($APTOF)) announced an update on their ongoing clinical study. Aptose Biosciences Inc. is conducting a...

1M ago

APTOF

Aptose’s Tuspetinib Shows Promising Results in AML Treatment Trial

Aptose Biosciences ( ($TSE:APS) ) has issued an announcement. Aptose Biosciences announced promising results from its Phase 1/2...

2M ago

Aptose Secures $11.9M Loan for AML Therapy Development

The latest update is out from Aptose Biosciences ( ($TSE:APS) ). Aptose Biosciences has extended a loan agreement...

2M ago

Aptose Biosciences Announces Executive Retention Awards

Aptose Biosciences ( ($TSE:APS) ) just unveiled an announcement. On August 19, 2025, Aptose Biosciences Inc announced retention...

3M ago

Aptose Biosciences Secures Funding for Drug Development

Aptose Biosciences ( ($TSE:APS) ) has issued an update. On August 22, 2025, Aptose Biosciences held its reconvened...

3M ago

Aptose Biosciences shares to delist from Nasdaq as of April 2

Aptose Biosciences (APTO) announced that the Nasdaq Hearings Panel has determined to delist the common shares of the...

8M ago

APTO

Aptose Biosciences price target raised to $6 from $2 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Aptose Biosciences (APTO) to $6 from $2...

8M ago

APTO

Aptose Biosciences reports FY24 EPS ($36.38) vs. ($227.43) last year

“During 2024 and into 2025, we continue to advance our lead investigational drug tuspetinib in combination with venetoclax...

8M ago

APTO

APS FAQ

What was Aptose Biosciences’s price range in the past 12 months?

Aptose Biosciences lowest stock price was C$1.02 and its highest was C$16.50 in the past 12 months.

What is Aptose Biosciences’s market cap?

Aptose Biosciences’s market cap is $5.10M.

When is Aptose Biosciences’s upcoming earnings report date?

Aptose Biosciences’s upcoming earnings report date is Mar 24, 2026 which is in 113 days.

How were Aptose Biosciences’s earnings last quarter?

Aptose Biosciences released its earnings results on Nov 13, 2025. The company reported -C$2.824 earnings per share for the quarter, missing the consensus estimate of N/A by -C$2.824.

Is Aptose Biosciences overvalued?

According to Wall Street analysts Aptose Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aptose Biosciences pay dividends?

Aptose Biosciences does not currently pay dividends.

What is Aptose Biosciences’s EPS estimate?

Aptose Biosciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aptose Biosciences have?

Aptose Biosciences has 2,552,429 shares outstanding.

What happened to Aptose Biosciences’s price movement after its last earnings report?

Aptose Biosciences reported an EPS of -C$2.824 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.577%.

Which hedge fund is a major shareholder of Aptose Biosciences?

Currently, no hedge funds are holding shares in TSE:APS

Company Description

Aptose Biosciences

Aptose Biosciences Inc. (APS) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of highly differentiated therapeutics addressing unmet medical needs in oncology. The company specializes in developing targeted therapies for the treatment of hematologic malignancies and other life-threatening diseases. Aptose leverages a deep understanding of cancer biology to develop innovative small molecule cancer drugs.

Aptose Biosciences (APS) Earnings & Revenues

Historic Earnings Reports

APS Stock 12 Month Forecast

Average Price Target

C$2.42

▲(4.87% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"C$0","20":"C$20","40":"C$40","60":"C$60","80":"C$80"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.4272502853902536,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$2.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.4225522664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$2.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.4272502853902536,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$2.43</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,20,40,60,80],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.88,1.92209617579925,1.9641923515985005,2.006288527397751,2.048384703197001,2.0904808789962512,2.1325770547955014,2.174673230594752,2.216769406394002,2.2588655821932524,2.3009617579925026,2.343057933791753,2.3851541095910034,{"y":2.4272502853902536,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.88,1.9217347897230768,1.9634695794461536,2.0052043691692307,2.0469391588923074,2.0886739486153845,2.1304087383384616,2.172143528061538,2.2138783177846153,2.255613107507692,2.297347897230769,2.339082686953846,2.380817476676923,{"y":2.4225522664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.88,1.92209617579925,1.9641923515985005,2.006288527397751,2.048384703197001,2.0904808789962512,2.1325770547955014,2.174673230594752,2.216769406394002,2.2588655821932524,2.3009617579925026,2.343057933791753,2.3851541095910034,{"y":2.4272502853902536,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":79.2,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.8,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.299,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.8,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.2,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.9,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.75,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.649,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >